Amyotrophic lateral sclerosis (also referred to as ALS, Charkot’s disease, Charkot’s sclerosis or Lou Gehrig’s disease in English-speaking countries) or motor neuron disease, is progressive weakening of muscles and atrophy, from 2 to 5 years (rarely 7 years) by worsening, it causes a fatal outcome of 99.9%.
Amyotrophic lateral sclerosis manifests itself in the following symptoms:
- Muscle spasms
- Difficulty speaking and swallowing
- Unbalanced problem
- Increased deep reflexes or expansion of the reflexogenic zone
- Pathological reflexes
- Dangling foot
- Respiratory disorders
- Sudden and severe laughing or crying bouts
SVF Stem Cell Therapy in ALS Treatment
Following the stem cell transplantation to ALS patients who did not respond to medication or did not receive sufficient results, it is seen that 67% had weakness, improved appetite and psychological progress, and a decrease in spasticity intensity.
It has been reported that in about 34% of the patients, approximately 2 months after the stem cell transplantation, there was an increase in mobility and muscle strength in hands and feet, normalization of reflexes, decrease in fiber zones, better toes in daily work, decrease in dysphagia and dissatisfaction (improvement in pronunciation, swallowing, speaking).
For positive results to be achieved, 48% of patients are recommended to repeat treatment with annual periods. In 25% of cases, patients need regular 2-year stem cell transplant.
The SVF does not improve the actual cause of stem cell transplant disease because the true cause of the disease is not fully understood. However, it has a significant effect on pathological processes and helps preventing disease progression.Stem cells help increase the quality of life of ALS patients and prolong their life span.
- Mao Z, Zhang S, Chen H. Stem cell therapy for amyotrophic lateral sclerosis. Cell Regeneration. 2015;4:11. doi:10.1186/s13619-015-0026-7.
- Mazzini L et al. Stem cell treatment in Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2007; 265(1-2): 78-83.
- Silani V. Et al. Stem-cell therapy for amyotrophic lateral sclerosis. 2004;364: 200-202.
* Initiation of stem cell therapy is primarily a physician assessment and subsequent patient decision. DOKU BIOTECHNOLOGY is not a treatment practitioner. These results refer to the findings obtained as a result of scientific and clinical studies.